AIP-Texas joins NCPA
ALEXANDRIA, Va. — The Academy of Independent Pharmacists-Texas is the newest member of a group that represents the nation’s independent pharmacies.
The National Community Pharmacists Association said having AIP-Texas participants as members will “strengthen the voice of independent pharmacists and their patients.”
AIP-Texas promotes the practice of independent pharmacy in Texas by providing a forum for independents to exchange information and develop strategies, goals and objectives. AIP-Texas advocates on legislative and regulatory issues on behalf of independent pharmacists and their patients, both in Texas and across the United States, the NCPA said.
FDA approves test to monitor levels of Zortress in the bloodstream
SILVER SPRING, Md. —The Food and Drug Administration announced Friday the approval of Waltham, Mass.-based Thermo Fisher’s QMS Everolimus Immunoassay, a test that monitors the blood for levels of Novartis’ drug Zortress (everolimus).
Zortress is a drug used to prevent rejection of transplanted kidneys.
“QMS Everolimus is the first FDA-cleared test physicians can use to maintain appropriate levels of the immunosuppressant everolimus,” FDA Center for Devices and Radiological Health director Jeffrey Shuren said.
FDA approves Quixin generic
AMITYVILLE, N.Y. — The Food and Drug Administration has approved Hi-Tech Pharmacal’s generic version of a drug for eye infections.
Hi-Tech announced the approval of levofloxacin ophthalmic solution in the 0.5% strength, a treatment for bacterial conjunctivitis. The company plans to launch next month.
The drug is a generic version of Vistakon’s Quixin, which had sales of $2 million in 2010, according to IMS Health.